FibroGen’s Neff passes away

FibroGen Inc. (NASDAQ:FGEN) said Chairman and CEO Thomas Neff passed away unexpectedly over the weekend.

Neff founded FibroGen in 1993 to tackle fibrotic diseases, such as idiopathic pulmonary fibrosis. Since then he has led the company's development of lead candidate roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that is approved in China, and pamrevlumab, a human mAb against connective tissue growth factor in clinical development for IPF, pancreatic cancer and Duchenne muscular dystrophy (see “FibroGen’s Globetrotting”)...